<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>PURPOSE: To determine the incidence and risk factors for the development of new <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e> occurring after stem-cell transplantation (SCT) </plain></SENT>
<SENT sid="1" pm="."><plain>PATIENTS: Between January 1, 1974, and March 31, 2001, 3,372 patients underwent SCT at the University of Minnesota </plain></SENT>
<SENT sid="2" pm="."><plain>From these transplants, 147 posttransplant <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e> (PTMs) were identified in 137 patients </plain></SENT>
<SENT sid="3" pm="."><plain>RESULTS: Excluding <z:e sem="disease" ids="C0699893" disease_type="Neoplastic Process" abbrv="">nonmelanoma skin cancers</z:e> (n = 19) and <z:mp ids='MP_0002038'>carcinoma</z:mp>-in-situ (n = 5), the remaining 123 cases represented an 8.1-fold (95% confidence interval [CI], 6.7 to 9.6) increased risk of a PTM, an excess risk of 102.7 cases/10,000 persons/yr (age and sex adjusted) </plain></SENT>
<SENT sid="4" pm="."><plain>This includes a significantly elevated risk for developing <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) or <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>; standardized incidence ratio [SIR] = 300; 95% CI, 210 to 406), non-Hodgkin's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> including posttransplant <z:hpo ids='HP_0005523'>lymphoproliferative disorder</z:hpo> (PTLD; SIR = 54.3; 95% CI, 39.5 to 41.1), <z:e sem="disease" ids="C0019829" disease_type="Neoplastic Process" abbrv="hd">Hodgkin's disease</z:e> (SIR = 14.8; 95% CI, 3.9 to 32.9), or <z:e sem="disease" ids="C0280100" disease_type="Neoplastic Process" abbrv="">solid tumors</z:e> overall (SIR = 2.8; CI, 2.0 to 3.7) and in specific for <z:hpo ids='HP_0002861'>melanoma</z:hpo>, brain, and <z:e sem="disease" ids="C0026640" disease_type="Neoplastic Process" abbrv="">oral cavity tumors</z:e> </plain></SENT>
<SENT sid="5" pm="."><plain>The cumulative incidence for the development of any PTM was 6.9% (95% CI, 5.2 to 8.6) at 20 years post-SCT </plain></SENT>
<SENT sid="6" pm="."><plain>For PTLD (n = 43), the cumulative incidence plateaued at 1.4% (95% CI, 1.0 to 1.8) by 10 years post-SCT </plain></SENT>
<SENT sid="7" pm="."><plain>For <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> or <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>, the cumulative incidence plateaued at 1.4% (95% CI, 0.9 to 1.9) by 10 years post-SCT </plain></SENT>
<SENT sid="8" pm="."><plain>The cumulative incidence of developing a <z:e sem="disease" ids="C0280100" disease_type="Neoplastic Process" abbrv="">solid tumor</z:e> did not plateau and was 3.8% (95% CI, 2.2 to 5.4) at 20 years post-SCT </plain></SENT>
<SENT sid="9" pm="."><plain>CONCLUSION: These data reveal that the risk of PTMs, especially <z:e sem="disease" ids="C0280100" disease_type="Neoplastic Process" abbrv="">solid tumors</z:e>, continues to increase even 20 years after transplant, necessitating long-term close follow-up for these patients </plain></SENT>
</text></document>